# GLP-1s Like Ozempic May Help Lower Breast Cancer Risk
New research suggests that GLP-1 receptor agonists, drugs like Ozempic and Wegovy commonly prescribed for type 2 diabetes and weight loss, may reduce breast cancer risk. The connection appears to work through weight loss and improved metabolic health rather than direct drug effects on cancer cells.
Scientists have observed that obesity increases breast cancer risk, particularly in postmenopausal women. Excess body fat produces estrogen, which can fuel hormone-sensitive breast cancers. GLP-1 drugs like semaglutide work by slowing digestion, reducing appetite, and helping people lose significant weight. When users drop pounds, their estrogen levels typically fall, reducing cancer risk factors.
Researchers at several institutions are examining whether GLP-1 use directly correlates with lower breast cancer rates. Early studies show promise. A 2024 analysis found that people taking GLP-1 medications had fewer cancer diagnoses overall compared to those using older diabetes drugs. The breast cancer connection specifically relates to the weight loss these drugs produce.
Weight loss from GLP-1 medications averages 10 to 22 percent of body weight over two years in clinical trials. That magnitude of weight reduction alone reduces breast cancer risk substantially. Some experts believe the metabolic improvements beyond just weight loss may offer additional protection through reduced inflammation and better insulin sensitivity.
However, researchers caution against viewing GLP-1 drugs primarily as cancer prevention tools. These medications carry side effects including nausea, vomiting, and potential thyroid concerns. They work best for people with obesity or type 2 diabetes who need weight management anyway.
If breast cancer runs in your family or you have obesity-related health concerns, discuss GLP-1 options with your doctor. Combined with screening, exercise, and limited